Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

People who use drug coupon cards could be on the hook for higher costs this year. Photo: Jeffrey Greenberg / UIG via Getty Images

Consumers could soon face surprising increases in how much they have to pay for their prescription drugs, thanks to changes in the way health insurers and pharmacy benefit managers process coupons from drug manufacturers.

Why it matters: Midterm elections are coming up in the fall. High drug prices have enraged people across the political spectrum, and voters who already have trouble affording their prescriptions could be hit with another surprise.

How it works: Drug companies frequently offer coupon cards, commonly called "copay coupons," for patients who need their medicine. The consumers who use the coupons get a better deal, and the drug companies get a sales boost.

  • But studies show drug coupons raise costs across the board because they encourage people to get more expensive drugs even when cheaper options are available. Those costs filter through to insurance companies and policyholders.
  • Medicare prohibits copay coupons, essentially calling them kickbacks.

What's changing: Many companies that provide health insurance and drug coverage, notably UnitedHealthcare and Express Scripts, are instituting "copay accumulators" for this year.

  • Previously, when patients went to a pharmacy and used a copay coupon, the value of that coupon counted toward their deductible or out-of-pocket maximum. It's "a way to bridge people through their deductible so the employer or insurer pays," said Peter Bach, a researcher at the Memorial Sloan Kettering Cancer Center.
  • But now, with a copay accumulator, the coupon's value won't count toward patients' deductibles or out-of-pocket limits. Only true out-of-pocket payments will count.
  • What this means: Once patients use the full value of their drug coupons, they'll be on the hook for a lot more of the costs.

"In the short term, consumers are going to be potentially devastated by the sudden change in out-of-pocket spending," said Leemore Dafny, a health economist at Harvard who has studied the effects of drug copay coupons. "In the long term, it's a cost-control measure that is long overdue."

What we're hearing: Wall Street is nervous that copay accumulators will drive down sales for expensive drugs that treat chronic conditions, like AbbVie's blockbuster Humira.

  • "It is very likely that some patients will find this sudden increase in out-of-pocket costs unmanageable, leading to a reduction in volumes of specialty drugs," according to a January investor note from Credit Suisse's Vamil Divan.
  • Divan went on to say: "The fact that two of the leading health care insurance providers have initiated this restriction suggests to us that it could gain momentum as a major cost-containment measure."

The bottom line: Expect the health care industry to throw around the blame, while patients are caught in the middle again. Drug companies will say insurers and PBMs are restricting access to life-saving medicine, and insurers will blast big pharma for propping up sales with coupons that raise costs for everyone else.

  • "They'll point fingers at each other, and they'll both be right," Bach said.
  • "What's regrettable is it comes at the expense of patients who have a lot of chronic disease," Dafny said.

Go deeper

18 mins ago - Technology

Microsoft looks to leapfrog Big Tech competitors with major acquisitions

Data: CB Insights; Chart: Andrew Witherspoon/Axios

Microsoft is trying to leapfrog competitors like Google and Amazon as they face record antitrust scrutiny.

The big picture: The deals Microsoft has been eyeing are larger than its usual targets and bigger than those of its competitors.

Updated 28 mins ago - Economy & Business

Scoop: DraftKings readies major media push

Illustration: Sarah Grillo/Axios

DraftKings has hired Brian Angiolet, former senior vice president and chief business officer officer at Verizon, as the company’s first-ever chief media officer.

Details: Angiolet will lead a team responsible for evaluating potential media acquisitions and content efforts, sources tell Axios. The team will help vet future deals and content partnerships that the company will use to help drive customer referrals to its sportsbook.

Fallout over Daunte Wright shooting continues

A second night of protests over the police shooting of Daunte Wright unfolded in Brooklyn Center Tuesday, as a large crowd defied a curfew and pleas from city leaders to go home.

Driving the news: “We are going to get to the bottom of this. We are going to make sure that there’s justice, that this officer is held accountable," Brooklyn Center Mayor Mike Elliott told demonstrators in an effort to calm tensions after dark.

You’ve caught up. Now what?

Sign up for Mike Allen’s daily Axios AM and PM newsletters to get smarter, faster on the news that matters.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!